Quantcast

Industry news that matters to you.  Learn more

Rules-Base Medicine Gets Award to Develop Cancer Biomarker Assays

Rules-Based Medicine today said it has received an award for about $3 million to fund the research and development of more than double the number of cancer-associated biomarker assays in its new OncologyMap product.

New Research Profiles the State of Biomarkers in Product Development

Industry Standard Research (ISR) today announced the release of The State of Biomarkers in Drug Development report. 44 pharmaceutical and biotechnology professionals provided their strategies, insights, and predictions in this snapshot of a rapidly evolving market. In total, 37 significant pharma and biotech companies contributed to this endeavor.

Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced a collaborative study with Almac’s Diagnostics division for the Company’s doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108, aimed at determining LHRH receptor expression through the development of a companion diagnostic tool. Selection for treatment with AEZS-108 is determined on the basis of LHRH receptor expression, currently measured immunohistochemically. In humans, LHRH receptors are expressed in ovarian, endometrial, breast, bladder, prostate and pancreatic tumors. AEZS-108 is currently in Phase 2 trials for advanced LHRH receptor positive ovarian and endometrial cancer.

Phadia Chooses Aushon BioSystems’ Microarray Technology to Accelerate Diagnostic Allergen and Autoimmunity Assay Development

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announced today that Phadia, the world leader in allergy blood testing diagnostics, will utilize the Aushon 2470 Arrayer technology in its Multiplexing Diagnostics GmbH division. The 2470 will enable Phadia to advance its research efforts focusing on the characterization of new allergens, and the discovery of patterns in molecular diagnosis for allergy and autoimmunity.

TGen partner, PBS-Bio, makes first breakthrough drug analysis

Predictive Biomarker Sciences Inc. (PBS-Bio) has completed its first drug analysis, enabling Canadian biotech company PharmaGap Inc. to significantly advance a potentially significant anti-cancer medication.